LONDON (Reuters) - An experimental antibody drug from GlaxoSmithKline Plc has proved effective in tests for treating a rare disorder known as hypereosinophilic syndrome (HES), researchers said on Sunday.
LONDON (Reuters) - An experimental antibody drug from GlaxoSmithKline Plc has proved effective in tests for treating a rare disorder known as hypereosinophilic syndrome (HES), researchers said on Sunday.
